Clinical Trials

Phase 3 Active not recruiting

Waldenstrom Macroglobulinemia

NCT02477696 2025-11-20

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Phase 3 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 1 FDA

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT04189952 2025-05-31

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04402138 2025-05-13

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

15 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03623373 2025-05-04

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

13 enrolled 11 charts

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04657094 2025-04-27

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

4 enrolled 7 charts

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Phase 1 Completed

21 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04930536 2024-11-22

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Phase 4 Completed

103 enrolled 10 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03788291 2024-09-26

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

39 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase 1/2 Terminated

25 enrolled 11 charts

DLBCL

NCT02211014 2020-07-31

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Phase 1 Completed

27 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT02362048 2019-10-01

KEYNOTE144

77 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02537444 2019-09-25

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

78 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT02448303 2019-09-12

KEYNOTE166

74 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02454179 2019-09-12

KEYNOTE147